These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 22451619)

  • 21. Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven.
    Attard G; Reid AH; Olmos D; de Bono JS
    Cancer Res; 2009 Jun; 69(12):4937-40. PubMed ID: 19509232
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants.
    Mostaghel EA; Marck BT; Plymate SR; Vessella RL; Balk S; Matsumoto AM; Nelson PS; Montgomery RB
    Clin Cancer Res; 2011 Sep; 17(18):5913-25. PubMed ID: 21807635
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer.
    Bedoya DJ; Mitsiades N
    Expert Rev Anticancer Ther; 2012 Jan; 12(1):1-3. PubMed ID: 22149426
    [No Abstract]   [Full Text] [Related]  

  • 24. Abiraterone and increased survival in metastatic prostate cancer.
    Sonpavde G
    N Engl J Med; 2011 Aug; 365(8):766-7; author reply 767-8. PubMed ID: 21864181
    [No Abstract]   [Full Text] [Related]  

  • 25. Abiraterone acetate is well tolerated without concomitant use of corticosteroids.
    Attard G; Reid AH; de Bono JS
    J Clin Oncol; 2010 Oct; 28(29):e560-1; author reply e562. PubMed ID: 20805462
    [No Abstract]   [Full Text] [Related]  

  • 26. Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer.
    Li Z; Bishop AC; Alyamani M; Garcia JA; Dreicer R; Bunch D; Liu J; Upadhyay SK; Auchus RJ; Sharifi N
    Nature; 2015 Jul; 523(7560):347-51. PubMed ID: 26030522
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overcoming persistent dependency on androgen signaling after progression to castration-resistant prostate cancer.
    Yamaoka M; Hara T; Kusaka M
    Clin Cancer Res; 2010 Sep; 16(17):4319-24. PubMed ID: 20647476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.
    Cai C; Chen S; Ng P; Bubley GJ; Nelson PS; Mostaghel EA; Marck B; Matsumoto AM; Simon NI; Wang H; Chen S; Balk SP
    Cancer Res; 2011 Oct; 71(20):6503-13. PubMed ID: 21868758
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer.
    Eichholz A; Ferraldeschi R; Attard G; de Bono JS
    Mol Cell Endocrinol; 2012 Sep; 360(1-2):68-75. PubMed ID: 21986558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.
    Yin L; Hu Q
    Nat Rev Urol; 2014 Jan; 11(1):32-42. PubMed ID: 24276076
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Androgen-deprivation therapy in prostate cancer: clinical evidence and future perspectives].
    Pinto F; Calarco A; Totaro A; Sacco E; Volpe A; Racioppi M; D'Addessi A; Bassi PF
    Urologia; 2010; 77(2):71-83. PubMed ID: 20890863
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Abiraterone acetate: in metastatic castration-resistant prostate cancer.
    Yang LP
    Drugs; 2011 Oct; 71(15):2067-77. PubMed ID: 21985170
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer.
    Ang JE; Olmos D; de Bono JS
    Br J Cancer; 2009 Mar; 100(5):671-5. PubMed ID: 19223900
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting the adrenal gland in castration-resistant prostate cancer: a case for orteronel, a selective CYP-17 17,20-lyase inhibitor.
    Zhu H; Garcia JA
    Curr Oncol Rep; 2013 Apr; 15(2):105-12. PubMed ID: 23371447
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expanding treatment options for metastatic prostate cancer.
    Antonarakis ES; Eisenberger MA
    N Engl J Med; 2011 May; 364(21):2055-8. PubMed ID: 21612475
    [No Abstract]   [Full Text] [Related]  

  • 36. Castration-resistant prostate cancer: systemic therapy in 2012.
    Maluf FC; Smaletz O; Herchenhorn D
    Clinics (Sao Paulo); 2012; 67(4):389-94. PubMed ID: 22522765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate cancer-from steroid transformations to clinical translation.
    Chang KH; Sharifi N
    Nat Rev Urol; 2012 Dec; 9(12):721-4. PubMed ID: 23027067
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities.
    Payne H; Bahl A; Mason M; Troup J; De Bono J
    BJU Int; 2012 Sep; 110(5):658-67. PubMed ID: 22429837
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Castration resistant prostate cancer 2011].
    Miller K
    Aktuelle Urol; 2011 Mar; 42(2):95-102. PubMed ID: 21437832
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The European medicines agency review of abiraterone for the treatment of metastatic castration-resistant prostate cancer in adult men after docetaxel chemotherapy and in chemotherapy-naive disease: summary of the scientific assessment of the committee for medicinal products for human use.
    Gravanis I; Lopez AS; Hemmings RJ; Jiménez JC; Garcia-Carbonero R; Gallego IG; Giménez EV; O'Connor D; Giuliani R; Salmonson T; Pignatti F
    Oncologist; 2013; 18(9):1032-42. PubMed ID: 23966222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.